SIG-1451

SIG-1451 is a novel **non-steroidal anti-inflammatory compound** (NSAID) developed primarily for **atopic dermatitis** as a topical therapeutic. It inhibits **Toll-like receptor 4 (TLR4)** signaling, reducing inflammatory responses by suppressing phosphorylation of I-κB and downstream cytokine production, such as CCL2 and C3. In preclinical studies, intraperitoneal administration protected against light-induced photoreceptor degeneration in rats by attenuating microglial activation and retinal inflammation without directly preventing apoptosis, suggesting potential utility in retinal degenerative diseases like age-related macular degeneration (AMD).